A risk score model based on TGF-β pathway-related genes predicts survival, tumor microenvironment and immunotherapy for liver hepatocellular carcinoma

Springer Science and Business Media LLC - Tập 20 Số 1 - 2022
Jingsheng Liao1, Qi Liu1, Jingtang Chen1, Zhi‐Bin Lu1, Huiting Mo1, Jia Ju1
1Department of Medical Oncology, Affiliated Dongguan Hospital, Southern Medical University, 78 Wandao Road, Dongguan City, 523000, Guangdong Province, China

Tóm tắt

Abstract Background Transforming growth factor-beta (TGF-β) signal is an important pathway involved in all stages of liver hepatocellular carcinoma (LIHC) initiation and progression. Therefore, targeting TGF- β pathway may be a potential therapeutic strategy for LIHC. Prediction of patients’ tumor cells response requires effective biomarkers. Methods From 54 TGF-β-related genes, this research determined the genes showing the greatest relation to LIHC prognosis, and developed a risk score model with 8 TGF-β-related genes. The model divided LIHC patients from different datasets and platforms into low- and high-risk groups. Multivariate Cox regression analysis confirmed that the model was an independent prognostic factor for LIHC. The differences in genetic mutation, immune cell infiltration, biological pathway, response to immunotherapy or chemotherapy, and tumor microenvironment in LIHC samples showing different risks were analyzed. Results Compared with low-risk group, in the training set and test set, high-risk group showed shorter survival, lower stromal score and higher M0 macrophages scores, regulatory T cells (Tregs), helper follicular T cells. Moreover, high-risk samples showed higher sensitivity to cisplatin, imatinib, sorafenib and salubrinal and pyrimethamine. High-risk group demonstrated a significantly higher Tumor Immune Dysfunction and Exclusion (TIDE) score, but would significantly benefit less from taking immunotherapy and was less likely to respond to immune checkpoint inhibitors. Conclusions In general, this work provided a risk scoring model based on 8 TGF-β pathway-related genes, which might be a new potential tool for predicting LIHC.

Từ khóa


Tài liệu tham khảo

Sung H, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.

Vogel A, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:871–3. https://doi.org/10.1093/annonc/mdy510.

Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int. 2021. https://doi.org/10.1111/liv.15052. Epub ahead of print.

Yang JD, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589–604. https://doi.org/10.1038/s41575-019-0186-y.

Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–14. https://doi.org/10.1016/S0140-6736(18)30010-2.

Fabregat I, et al. TGF-beta signalling and liver disease. FEBS J. 2016;283:2219–32. https://doi.org/10.1111/febs.13665.

Tu S, Huang W, Huang C, Luo Z, Yan X. Contextual regulation of TGF-beta signaling in liver Cancer. Cells. 2019;8:1235. https://doi.org/10.3390/cells8101235.

Fabregat I, Caballero-Diaz D. Transforming growth factor-beta-induced cell plasticity in liver fibrosis and Hepatocarcinogenesis. Front Oncol. 2018;8:357. https://doi.org/10.3389/fonc.2018.00357.

Arrese M, et al. TGF-beta and Hepatocellular carcinoma: when a friend becomes an enemy. Curr Protein Pept Sci. 2018;19:1172–9. https://doi.org/10.2174/1389203718666171117112619.

Neuzillet C, et al. Perspectives of TGF-beta inhibition in pancreatic and hepatocellular carcinomas. Oncotarget. 2014;5:78–94. https://doi.org/10.18632/oncotarget.1569.

Katz LH, et al. TGF-beta signaling in liver and gastrointestinal cancers. Cancer Lett. 2016;379:166–72. https://doi.org/10.1016/j.canlet.2016.03.033.

Liberzon A, et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell systems. 2015;1:417–25. https://doi.org/10.1016/j.cels.2015.12.004.

Cancer Genome Atlas Research Network. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell. 2017;169:1327–1341.e1323. https://doi.org/10.1016/j.cell.2017.05.046.

Hoshida Y, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359:1995–2004. https://doi.org/10.1056/NEJMoa0804525.

Roessler S, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010;70:10202–12. https://doi.org/10.1158/0008-5472.Can-10-2607.

Grinchuk OV, et al. Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma. Mol Oncol. 2018;12:89–113. https://doi.org/10.1002/1878-0261.12153.

Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for Cox's proportional hazards model via coordinate descent. J Stat Softw. 2011;39:1–13. https://doi.org/10.18637/jss.v039.i05.

Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32:5381–97. https://doi.org/10.1002/sim.5958.

Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50. https://doi.org/10.1073/pnas.0506580102.

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https://doi.org/10.1186/s13059-014-0550-8.

Cibulskis K, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213–9. https://doi.org/10.1038/nbt.2514.

Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods Mol Biol (Clifton, N.J.). 2018;1711:243–59. https://doi.org/10.1007/978-1-4939-7493-1_12.

Yoshihara K, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. https://doi.org/10.1038/ncomms3612.

Roh W, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017;9:eaah3560. https://doi.org/10.1126/scitranslmed.aah3560.

Yang W, et al. Genomics of drug sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955–61. https://doi.org/10.1093/nar/gks1111.

Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One. 2014;9:e107468. https://doi.org/10.1371/journal.pone.0107468.

Rody A, et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 2009;11:R15. https://doi.org/10.1186/bcr2234.

Chen J, Gingold JA, Su X. Immunomodulatory TGF-beta signaling in hepatocellular carcinoma. Trends Mol Med. 2019;25:1010–23. https://doi.org/10.1016/j.molmed.2019.06.007.

Yang Y, et al. The role of TGF-beta signaling pathways in Cancer and its potential as a therapeutic target. Evid Based Complement Alternat Med. 2021;2021:6675208. https://doi.org/10.1155/2021/6675208.

Giannelli G, Mazzocca A, Fransvea E, Lahn M, Antonaci S. Inhibiting TGF-beta signaling in hepatocellular carcinoma. Biochim Biophys Acta. 2011;1815:214–23. https://doi.org/10.1016/j.bbcan.2010.11.004.

Gonzalez-Sanchez E, et al. The TGF-beta pathway: a pharmacological target in hepatocellular carcinoma? Cancers (Basel). 2021;13:3248. https://doi.org/10.3390/cancers13133248.

Chen J, et al. Analysis of genomes and transcriptomes of hepatocellular carcinomas identifies mutations and gene expression changes in the transforming growth factor-beta pathway. Gastroenterology. 2018;154:195–210. https://doi.org/10.1053/j.gastro.2017.09.007.

Khemlina G, Ikeda S, Kurzrock R. The biology of hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer. 2017;16:149. https://doi.org/10.1186/s12943-017-0712-x.

Long J, et al. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine. 2019;42:363–74. https://doi.org/10.1016/j.ebiom.2019.03.022.

Kavanagh E, Joseph B. The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochim Biophys Acta. 2011;1816:50–6. https://doi.org/10.1016/j.bbcan.2011.03.002.

Guo H, et al. Prognostic significance of co-expression of nm23 and p57 protein in hepatocellular carcinoma. Hepatol Res. 2010;40:1107–16. https://doi.org/10.1111/j.1872-034X.2010.00721.x.

Bai Y, et al. Identification of seven-gene hypoxia signature for predicting overall survival of hepatocellular carcinoma. Front Genet. 2021;12:637418. https://doi.org/10.3389/fgene.2021.637418.

Witt AE, et al. Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. Oncogene. 2017;36:1707–20. https://doi.org/10.1038/onc.2016.337.

Ler SY, et al. HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a southeast Asian population. Oncol Rep. 2015;34:2238–50. https://doi.org/10.3892/or.2015.4263.

Vachher M, Arora K, Burman A, Kumar B. NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas. J Cell Biochem. 2020;121:3010–23. https://doi.org/10.1002/jcb.29560.

Zhu Z, et al. Comprehensive analysis reveals CTHRC1, SERPINE1, VCAN and UPK1B as the novel prognostic markers in gastric cancer. Transl Cancer Res. 2020;9:4093–110. https://doi.org/10.21037/tcr-20-211.

Mazzoccoli G, et al. ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer. J Cancer Res Clin Oncol. 2012;138:501–11. https://doi.org/10.1007/s00432-011-1126-6.

Jin Y, Liang ZY, Zhou WX, Zhou L. Expression, clinicopathologic and prognostic significance of plasminogen activator inhibitor 1 in hepatocellular carcinoma. Cancer Biomark. 2020;27:285–93. https://doi.org/10.3233/cbm-190560.

Lin Z, Xu Q, Miao D, Yu F. An inflammatory response-related gene signature can impact the immune status and predict the prognosis of hepatocellular carcinoma. Front Oncol. 2021;11:644416. https://doi.org/10.3389/fonc.2021.644416.

Wu G, et al. High levels of BMP2 promote liver Cancer growth via the activation of myeloid-derived suppressor cells. Front Oncol. 2020;10:194. https://doi.org/10.3389/fonc.2020.00194.

Sun Z, et al. Construction of a prognostic model for hepatocellular carcinoma based on Immunoautophagy-related genes and tumor microenvironment. Int J Gen Med. 2021;14:5461–73. https://doi.org/10.2147/ijgm.S325884.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 20 Số 1

Thông tin tác giả